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ABSTRACT
Antibiotic resistance is an emerging threat worldwide, endangering the treatment of serious diseases. Widespread resistance to beta-lactam antibiotics 
among Gram-negative bacteria (GNB) is a serious threat to the currently used antibacterial therapy. Extended-spectrum beta-lactamases (ESBLs) are 
a group of enzymes capable of hydrolyzing extended-spectrum cephalosporins and are inhibited by clavulanic acid. These enzymes are a major cause 
of hospital-acquired infection and community-acquired infections caused by E. coli (Escherichia coli). E. coli forms a part of normal intestinal flora 
and is an important reservoir of the antibiotic-resistant genes for ESBLs. These resistant antibiotic genes can be easily spread among GNB as these 
are carried on plasmids. Fecal carriers of ESBL producing E. coli in hospitalized patients and in community can be a reservoir for person-to-person 
transmission strengthening their dissemination. Over the last few decades, there had been a considerable increase in the emergence and spread 
of antimicrobial-resistant enzymes favoring the predominance of antibiotic-resistant bacteria which results in morbidity, mortality, and increased 
hospital expenditure. The gastrointestinal tract plays an important role in development of antibiotic-resistant microorganism and harboring the 
microorganisms as commensal. Antibiotic consumption may lead to alteration in the genome of the microorganisms leading to emergence of resistant 
microorganisms. The resistant microorganisms may then spread into the environment through faces aiding dissemination of the resistant genes.
Keywords: Morbidity, Mortality, Extended-spectrum beta-lactamases, Escherichia coli.
INTRODUCTION
Resistance to antibiotics has posed a serious threat to both healthcare 
settings and community. The overuse and misuse of antibiotics has led to 
the bacteria to counter the effects of antibiotics by developing different 
resistant strategies [1]. A major consequence of antibiotic selection pressure 
is the emergence and spread of multidrug-resistant pathogens such as 
methicillin-resistant Staphylococcus aureus, Metallo-beta-lactamases 
(MBL) Pseudomonas, vancomycin-resistant  S. aureus, extended-spectrum 
beta-lactamases (ESBLs)-producing bacteria, Klebsiella pneumonia 
carbapenemase-producing bacteria, vancomycin-resistant Enterococcus, 
and multidrug-resistant Mycobacterium tuberculosis [2]. Among all these, 
the ESBL-producing Gram-negative bacteria (GNB) have disseminated 
across the globe since its first description in 1983 [3].
Beta-lactam antibiotics such as penicillins and cephalosporins work by 
inhibiting enzymes responsible for the cell wall synthesis of bacteria. 
Beta-lactam antibiotics were the most common antibiotics used widely 
to treat infections caused by GNB. An excessive and continuous use of 
these antibiotics had promoted genetic mutations in the bacteria that 
benefitted them to expand their activity against several classes of beta-
lactam antibiotics by producing ESBLs [4]. ESBLs are a group of enzymes 
conferring resistance to beta-lactam ring-containing antibiotics such as 
penicillins; first-, second-, and third-generation cephalosporins and 
aztreonam (but not the cephamycins or carbapenems) and are inhibited 
by beta-lactamase inhibitor such as clavulanic acid, sulbactam, and 
tazobactam [5]. The genes encoding for ESBLs are located on plasmids 
and thus can be transferred within and between different bacterial 
species by transformation, conjugation, or transduction process [6]. The 
plasmid-mediated transfer of ESBLs has resulted increase resistance to 
non-beta-lactam antibiotics such as trimethoprim-sulfamethoxazole, 
aminoglycosides, and fluoroquinolones, tetracyclines as plasmids 
may carry genes for conferring multidrug resistance presenting 
an additional challenge for controlling infections caused by ESBL-
producing pathogens [7].
Escherichia coli is a GNB commonly found both in pathogenic as well as 
non-pathogenic feces. The normal commensal E. coli may carry genes 
for antimicrobial resistance that can be transferred to the pathogenic 
E. coli, so the commensal resistant bacteria of the gut are also a reason 
for concern as they can be a cause of dissemination of the antibiotic-
resistant genes [8,9].
BETA-LACTAM ANTIBIOTICS: MECHANISM OF ACTION
Antibiotics have long been considered as the “magic bullet” that 
would end infectious diseases. They act against bacteria by one of 
the several ways such as inhibition of cell wall synthesis, inhibition 
of protein synthesis, impeding nucleic acid synthesis, cell membrane 
disorganization, or inhibition of a metabolic pathway [10]. Beta-lactam 
antibiotics include penicillins, cephalosporins, carbapenems, and 
monobactams. These antibiotics have in common a chemical structure 
that includes a three-carbon, one-nitrogen cyclic amine structure 
known as the beta-lactam ring. The side chain associated with the 
beta-lactam ring is a variable group attached to the core structure by 
a peptide bond; the side chain variability contributes to antibacterial 
activity [11]. They act by irreversible inhibition of carboxypeptidases 
and transpeptidases. These enzymes, also called as penicillin-binding 
proteins (PBPs) as they can bind irreversibly to the beta-lactam ring, 
help synthesis of cell wall of bacteria by catalyzing the cross-linking 
of D-alanine-D-alanine amino acid residues which present in the 
nascent peptidoglycan layers. Beta-lactam antibiotics share a structural 
similarity with the D-alanine amino acid residue present in the cell wall. 
Beta-lactam ring binds to the serine residue of the active site of PBP 
impeding the binding of D-alanine residue. This irreversible inhibition 
of PBPs inhibits cell wall synthesis, ultimately resulting in death of 
bacterial cell by activation of an autolytic system [12,13].
The resistance to beta-lactam antibiotics may be natural or may 
be acquired through genetic mutations or gene transfer. GNB have 
developed resistance to beta-lactam antibiotics by producing beta-
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lactam hydrolyzing enzymes called as beta-lactamases and Gram-
positive bacteria have conferred resistance by producing an altered PBP 
which is insensitive to beta-lactams [14].
AN INSIGHT INTO THE HISTORY OF ESBLS
The beginning of antibiotic era with the discovery of penicillin by 
Alexander Fleming in the year 1928 is marked by the consecutive 
development of antimicrobial resistance among different pathogens. 
Alexander Fleming in 1928 observed the growth of a mould of the 
genus Penicillium inhibiting the growth of bacteria in close vicinity 
of the mould. He identified that the mould produces an antibacterial 
substance called penicillin [15]. Even before the introduction of 
penicillin for the therapeutic use, a bacterial enzyme penicillinase 
was discovered by Abraham and Chain in 1940. Only after few years 
of introduction of penicillin for clinical use, penicillin-resistant beta-
lactamases were reported in various Gram-positive and GNB. These 
beta-lactamases were thought to break down the beta-lactam ring of 
the antibiotic resulting in ineffective antibiotic [12]. The first plasmid-
mediated β-lactamase in GNB was temoniera (TEM)-1 which was 
described in the early 1960s.
To counter the effect of beta-lactamases, broad-spectrum cephalosporin 
was introduced and they remained the first line of treatment for over 
20 years. However, soon after the availability of these antibiotics, 
enzymes resistant to broad-spectrum cephalosporins emerged known 
as ESBLs. In 1983, the first report of bacteria producing ESBLs was 
published. TEM was named so as it was first found in E. coli isolated 
from the blood of a patient named Temoneira from Greece [5]. In these 
20 years, many new antibiotics were developed to treat infections to 
resist the action of beta-lactamases. However, with the discovery of 
each new antibiotic, a new class of beta-lactamases has emerged such 
as the use of broad-spectrum cephalosporins has lead the development 
of broad-spectrum beta-lactamases (TEM-1, SHV-1) which have 
emerged as a result of single nucleotide mutation in the TEM or SHV 
beta-lactamases. Widespread use of third-generation cephalosporins 
and aztreonam is believed to be the predominant cause of mutations in 
the earlier discovered broad-spectrum beta-lactamases (TEM, SHV) and 
has led to the development of ESBLs. The term ESBL was first used by 
Phillippon, so that they can be differentiated from the broad-spectrum 
beta-lactamases [16]. By the end of 20th century, many studies have been 
published studying the recovery of ESBLs from various clinical isolates 
and in different parts of the world [17]. Some of the studies have also 
proposed the use of inhibitors of beta-lactamases such as tazobactam 
for treating infections caused by ESBL-producing bacteria [12].
ESBL-PRODUCING E. COLI IN THE GUT: A SERIOUS THREAT
Human gastrointestinal tract (GIT) harbors a large number of bacteria, 
and E. coli forms one of the largest groups, so there is an important 
role played by the gut in the acquisition and transmission of resistant 
pathogens [9]. E. coli is a GNB belonging to the family Enterobacteriaceae 
and colonizes the GIT of the human forming the most abundant 
facultative anaerobe of the human intestinal microflora. Although E. coli 
is found as a commensal microorganism in the intestine of human, 
there are variants of E. coli that are pathogenic as well. Pathogenic 
strains can be classified as intestinal pathogens causing diarrhea and 
extraintestinal pathogens causing a variety of other infections including 
urinary tract infections, meningitis, and septicemia [18]. E. coli presents 
as gut normal microflora may carry antibiotic-resistant genes on 
plasmids. Pathogenic diarrhea causing strains of E. coli can acquire 
resistant genes from the commensal E. coli in the intestine. Due to the 
augmented use of antibiotics, the sensitive strains of E. coli are killed 
allowing a more resistant ESBL-producing E. coli to survive and grow 
rapidly to increase in number. These resistant bacteria may then spread 
to the other person through environment contaminated with faces of 
these persons [19]. Poor hand hygiene and close contact with the cattle 
harboring the resistant E. coli can be an important contributing factors 
for the spread of ESBL-producing E. coli from a common source or from 
person to person [20].
CLASSIFICATION OF BETA-LACTAMS AND TYPES OF ESBL
More than 200 types of ESBL are known till now. There are different 
schemes for the classification of beta-lactams. The two major 
classification schemes followed for classifying beta-lactams into 
different categories are the Ambler molecular classification and 
the Bush-Jacoby-Medeiros functional classification [21]. Ambler 
classification scheme divides β-lactamases into Class A, Class B, Class C, 
and Class D enzymes on the basis of protein sequence (amino acid 
similarity). In the Ambler classification scheme, β-lactamases of Classes 
A, C. and D are serine β-lactamases. In contrast, the Class B enzymes 
are MBL. With the exception of OXA-type enzymes (which are Class D 
enzymes), the ESBLs are of molecular Class A [3].The majority of ESBLs 
identified in clinical isolates to date have been SHV or TEM types, which 
have evolved from narrow-spectrum β-lactamases such as TEM-1,2 
and SHV-1. The Bush-Jacoby-Medeiros classification scheme also called 
as functional classification scheme classifies beta-lactamase based on 
substrate and inhibitor profile. According to this scheme, ESBL belongs 
to the “2be” Group or 2d Group (OXA type ESBL). The 2be designation 
shows that these enzymes are derived from Group 2b beta-lactamases 
(for example, TEM-1, TEM-2, and SHV-1); the “e” of 2be denotes that 
the beta-lactamases have an extended spectrum. The ESBLs derived 
from TEM-1, TEM-2, or SHV-1 differ from their progenitors by as 
few as one amino acid. This has resulted in a profound change in the 
enzymatic activity of the ESBLs so that they can now hydrolyze the 
third-generation cephalosporins or aztreonam, hence the extension of 
spectrum compared to the parent enzymes [21]. Table 1 shows the Bush 
Jacoby functional classification and Amber molecular classification of 
ESBL along with their characteristics.
EPIDEMIOLOGY OF ESBL-PRODUCING E. COLI
Antimicrobial resistance is rapidly spreading across the globe and 
entails a significant threat to public health. Antibiotic resistance 
increases the morbidity, mortality, and costs of treating infectious 
diseases [22,23]. The gut plays a vital role in the development of 
antibiotic resistance, and the emergence of resistant microorganisms 
in the gut may be related to ingestion- or antibiotic-induced alterations 
in microorganisms. The resistant organisms then contaminate the 
environment. Asymptomatic fecal carriage of ESBL-producing bacteria 
had been reported from several countries and continents with wide 
differences in carriage rates between geographic areas. Over the 
years, prevalence of ESBL-producing E. coli has increased enormously. 
Various studies have documented the prevalence and susceptibility 
of ESBL-producing E. coli, and each one had reported quite different 
ESBL rates. As mentioned earlier also, ESBLs were first described in 
1983 from Germany and England. Various surveys conducted across 
the region had demonstrated the geographical variation. In a survey of 
laboratories in the Netherlands, <1% of E. coli and K. pneumoniae strains 
possessed ESBL [24]. While in another study conducted in France and 
Italy, ceftazidime resistance was observed in as many as 40% of strains 
of K. pneumonia [25]. The first ESBL-producing organisms were first 
reported in the US in 1988 [26].
A study conducted in Vietnam observed a prevalence of 87.4% of 
GNB from various clinical specimens out of a total 350 isolates. 
Of these GNB isolates, 88.9% were Enterobacteriaceae, of which 
14.7% were ESBL-positive [27]. A study conducted by Ko et al., at 
South Korea, documented 22.4% of K. pneumoniae isolates and 10.2% 
of E. coli isolates as ESBL producers [28]. In a study from India, the 
percentage of ESBL-positive isolates was found to be elevated, with 
23.1% of isolates being ESBL-positive [29]. Of the isolates from India, 
48.4% of isolates were E. coli and 51.6% were K. pneumoniae [30]. 
ESBL prevalence of 30-60% of from intensive care units in Brazil, 
Colombia, and Venezuela had been reported [31-34]. Moreover, 
several studies had been conducted to test the prevalence fecal 
carriage of ESBL-producing GNB as these carriers can form important 
reservoirs for the transmission of hospital-acquired infection (HAI) 
and community-acquired infections caused by these bacteria. In a 
study conducted at South Africa by Mahomed and Mahomed out of 
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300 samples analyzed, E. coli isolates were obtained from 97 stool 
samples and K. pneumoniae from 12 patients only. ESBL production 
was positive only in 3 E. coli isolates (3.1%) and 11 isolates out of 
12 K. pneumoniae were ESBL-positive. The combined fecal carriage of 
ESBL-producing E. coli and K. pneumoniae was 4.7% [35]. Reuland et 
al. in a study determined the rate of fecal carriage of ESBL-producing 
Enterobacteriaceae in the Dutch community in the Netherlands. Out 
of the total 720 samples, 73 of them were tested positive for ESBL-
producing Enterobacteriaceae, among which the predominant was 
E. coli [36]. In contrast, rates reported in Europe never exceeded 
10%, with the exception of a recent report of 11.6% observed in 
2011 among patients on admission to a geriatric unit in Belgium. 
Community carriage in Africa has been studied very poorly. Reported 
rates appear to be quite high, from 10.0% in Senegal [37] to 30.9% in 
Niger [38]. In a study conducted in a Tertiary Care Hospital in Chennai, 
India, a high prevalence of ESBL producers was observed. Higher 
resistance rate was noted for amoxyclav, ciprofloxacin, cefotaxime, 
ceftazidime, and ertapenem [39]. A study carried out in Coimbatore, 
India, showed that among 49 isolates, E. coli registered its prevalence 
in about 44 samples followed by Klebsiella spp. and Pseudomones spp. 
[40]. Thus, the reported prevalence of carriage of ESBL-producing 
bacteria may be influenced by characteristics of the population under 
study such as the geographic area, previous use of antibiotics, and 
healthcare environment.
PHENOTYPIC METHODS FOR THE DETECTION OF ESBL 
PRODUCTION IN E. COLI ISOLATES
Phenotypic detection of ESBL-producing E. coli isolates in clinical 
laboratory can be done by performing various screening and 
confirmatory tests according to the guidelines lead by clinical laboratory 
standard institute [41].
Screening methods for ESBL producers
Susceptibility of positive E. coli to third-generation cephalosporins is 
detected by performing antibiotic susceptibility test on Mueller-Hinton 
agar using a 0.5 McFarland standard inoculum. Screening method 
for detection of ESBL production is based on measuring the zone of 
inhibition. E. coli isolates may be regarded as positive for screening test 
for ESBL production under the following conditions as shown in Table 2.
BROTH MICRODILUTION METHOD
Broth microdilution test can be performed with Mueller-Hinton broth 
to determine the minimum inhibitory concentration. A positive test 
for ESBL-producing E. coli isolates is indicated by a MIC ≥8 µg/ml for 
cefpodoxime, MIC ≥2 µg/ml for ceftazidime, aztreonam, cefotaxime, or 
ceftriaxone.
SELECTIVE MEDIUM FOR DETECTION OF ESBL-PRODUCING E. COLI
Screening can also be made by the use of selective medium such as 
chrom ID ESBL agar, Brilliance ESBL agar, and HiCrome ESBL agar. 
ESBL-producing E. coli isolates produce blue-violet colonies on chrom 
ID ESBL agar and pink to burgundy colonies on Brilliance ESBL agar and 
either pink or purple colonies on HiCrome ESBL agar.
The isolates showing positive screening test are then tested further by 
confirmatory methods for ESBL detection as positive screening does 
not necessarily rule out the production of ESBL.
PHENOTYPIC CONFIRMATORY METHODS FOR THE DETECTION OF 
ESBL PRODUCTION
Double disc synergy test
Standardized inoculums of the test isolate are swabbed on the surface 
of a Mueller-Hinton agar plate. A combination disc, such as ceftazidime 
and clavulanic acid (30/10 mcg), piperacillin and tazobactam disc 
(100/10 mcg), was placed at the center surface of the plate. Disc 
containing 30 mcg of ceftazidime, cefotaxime, ceftriaxone, and 10 mcg of 
cefpodoxime was placed at a distance of 1.8 cm away from the central disc.
An extension in the zone of inhibition around the peripheral disc 
toward the centrally placed ceftazidime/clavulanic acid disc indicated 
ESBL production. An advantage of this method is that the method is 
relatively simple.
Combined disc test (inhibitor potentiated disc test)
Cephalosporins disc (cefotaxime 30 mcg, ceftazidime 30 mcg, and 
cefpodoxime 30 mcg) with or without clavulanic acid, 10 mcg, was 
placed on the Mueller-Hinton agar incorporated with the test organism. 
An increase in the inhibition zone diameter of ≥5 mm in cephalosporins 





Characteristics Examples of enzymes
1 C Cephalosporinases, chromosomal enzymes, resistant to clavulanic 
acid
E. coli AmpC, P99, ACT-1, CMY-2, FOX-1, MIR-1
2a A Penicillinase, greater hydrolysis of benzylpenicillin than 
cephalosporins, inhibited by clavulanic acid
PC1
2b A Broad-spectrum beta-lactamases inhibited by clavulanic acid and but 
not by EDTA
TEM-1, TEM-2, SHV-1
2be A ESBLs, inhibited by clavulanic acid TEM-3, SHV-2, CTX-M-15
2br A Penicillinases not inhibited by clavulanic acid and EDTA TEM-30, SHV-10
2c A Enzymes hydrolyzing carbenicillin, inhibited by clavulanic acid but 
not by EDTA
PSE-1, CARB-3
2d A Enzymes hydrolyzing cloxacillin OXA-1, OXA-10
2e A Extended-spectrum
Cephalosporins, inhibited by clavulanic acid but not by aztreonam
CepA
2f A Enzymes hydrolyzing carbapenems, inhibited by clavulanic acid KPC-2, IMI-1,
SME-1
3 B Metalloenzymes that hydrolyze carbapenems and other beta-lactams 
except monobactams. Not inhibited by clavulanic acid
CphA, Sfh-1
4 D Miscellaneous enzymes that do not fit into other groups
EDTA: Ethylenediaminetetraacetic acid, ESBLs: Extended-spectrum beta-lactamases
Table 2: Screening by disc diffusion method
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disc combined with clavulanic acid, compared to cephalosporins alone, 
indicated ESBL production.
Risk factors for acquisition of ESBL
The prevalence of ESBLs among clinical isolates varies between 
countries and from institution to institution. Several studies have 
already revealed various risk factors associated with colonization and 
infection with ESBL-producing organisms. In prolonged hospital stay, 
patients on medical devices such as urinary catheters, and central 
venous lines have been associated with infections by these organisms. 
Further, surgical procedures and indiscriminate use of antibiotics are 
added risk factors for the acquisition of ESBL-producing organisms. 
Presence of highly resistant pathogens in hospital sewage may result in 
transmission of resistant bacteria from environment to human.
Table 3 also describes various studies conducted across the world in 
different years to study the prevalence and the associated risk factors 
of ESBL-producing E. coli and other GNB.
CONCLUSIONS
Colonization with multidrug-resistant isolates, including ESBL 
producing isolates, is one of the significant risk factors for infection. 
Therefore, importance of detection of carriers of antimicrobial-resistant 
bacteria in hospitalized patients as well as in community is of utmost 
value. Antibiotic selection pressure in hospital may be the contributing 
factor for the presence of large number of carriers harboring resistant 
bacteria. By minimizing selective pressure through more judicious use of 
antibiotics, we may well be able to maintain antimicrobial susceptibility 
patterns at a level and we can tackle with. It was observed that healthy 
individuals also carried the commensal ESBL-producing E. coli in their 
gut in a high percentage. The occurrence of these ESBL-positive E. coli 
strains as colonizers in the community indicates a reservoir outside the 
hospitals that should be taken seriously regarding implementation of 
screening and hygiene precautions for prevention of infections with 
these drug-resistant bacteria.
Strict adherence to patient hygiene and infection control practices 
may be enforced to curtail hospital acquired infections. Rational 
use of antibiotics would substantially decrease pressure on the gut 
microflora and thereby limit acquisition of resistant genes among these 
microorganisms. There is a need to have stringent local and national 
research and surveillance efforts to monitor resistance pattern of 
commensal E. coli.
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